Altasciences at ARVO 2025: An Eye on the Future of Ophthalmic Drug Development by Gretchen Green
Altasciences recently attended and exhibited at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held at the Salt Palace Convention Center against the stunning backdrop of downtown Salt Lake City, Utah—arguably one of the most scenic U.S. conference locations.
CNS Drug Development Solutions, Simplified.
The Golden Era of GLP-1 Drugs: How Will it Impact Medicine and Society? by Dr. Gaetano Morelli MD, Chief Medical Officer and Executive Vice President Medical Affairs
Case Study: Two Examples of Successful Automation Integration at Altasciences for Pharmacokinetic Studies
By Martin Rougée, Optimization Scientist, Bioanalytical Operations
Automation offers several advantages to any industry. For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. For biotechnology and pharmaceutical companies, automation can decrease their drug-to-market development time and remain financially competitive in an evolving market.
Strategy for Addressing Specificity Challenges in Quantitation of Etonogestrel in Human Plasma by LC-MS/MS
Development of the Subject-Rated Comprehensive Drug Withdrawal Scale (CDWS) to Evaluate the Physical Dependence Potential of Investigational Drugs
Practical Considerations for the Evaluation of Physical Dependence and Drug Withdrawal for Novel CNS-Active Drugs in Clinical Trials
Navigating the Unchartered Territory of Assessing Psychedelics in Human Abuse Potential Studies